FDA Approves BYSANTI for Bipolar I and Schizophrenia
WASHINGTON, Feb. 20, 2026 — Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™...
CNS drug development
Advertisement
Meta-Analysis Reveals Drivers of Placebo Response in GAD
BOSTON, Feb. 20, 2026 — Seaport Therapeutics announced new findings from a comprehensive meta-analysis examining how clinical trial design...
Alto Completes Phase 2 Enrollment for CIAS Drug
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
Beacon, Takeda Expand AI Neurobiomarker Partnership for Narcolepsy
Boston, Massachusetts — November 19, 2025 — Beacon Biosignals has announced a multi-year expansion of its strategic collaboration with...
Emulate Launches Brain-Chip R1 for Neurology Drug Innovation
BOSTON, MA — November 18, 2025 — Emulate, Inc. has announced the launch of its next-generation Brain-Chip R1, a...
Advertisement
